{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:24Z","timestamp":1791488244362,"version":"4.3.4"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis C (HCV) reinfection studies have not focused on primary healthcare services in Australia, where priority populations including people who inject drugs (PWID) typically engage in healthcare. We aimed to describe the incidence of HCV reinfection and associated risk factors in a cohort of people most at risk of reinfection in a real-world community setting. We conducted a secondary analysis of routinely collected HCV testing and treatment data from treatment episodes initiated with direct-acting antiviral (DAA) therapy between October 2015 and June 2021. The overall proportion of clients (N = 413) reinfected was 9% (N = 37), and the overall incidence rate of HCV reinfection was 9.5\/100PY (95% CI: 6.3\u201314.3). Reinfection incidence rates varied by sub-group and were highest for Aboriginal and\/or Torres Strait Islander people (20.4\/100PY; 95% CI: 12.1\u201334.4). Among PWID (N= 321), only Aboriginality was significantly associated with reinfection (AOR: 2.73, 95% CI: 1.33\u20135.60, p = 0.006). High rates of HCV reinfection in populations with multiple vulnerabilities and continued drug use, especially among Aboriginal and Torres Strait Islander people, highlight the need for ongoing regular HCV testing and retreatment in order to achieve HCV elimination. A priority is resourcing testing and treatment for Aboriginal and\/or Torres Strait Islander people. Our findings support the need for novel and holistic healthcare strategies for PWID and the upscaling of Indigenous cultural approaches and interventions.<\/jats:p>","DOI":"10.3390\/v16060957","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T10:42:34Z","timestamp":1718361754000},"page":"957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C (HCV) Reinfection and Risk Factors among Clients of a Low-Threshold Primary Healthcare Service for People Who Inject Drugs in Sydney, Australia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-3777","authenticated-orcid":false,"given":"Phillip","family":"Read","sequence":"first","affiliation":[{"name":"Kirketon Road Centre, Kings Cross, P.O. Box 22, Sydney, NSW 1340, Australia"},{"name":"Kirby Institute, UNSW Australia, Sydney, NSW 2032, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce Zi Huan","family":"Tang","sequence":"additional","affiliation":[{"name":"UNSW Medicine and Health, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Silins","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre, Kings Cross, P.O. Box 22, Sydney, NSW 1340, Australia"},{"name":"National Drug and Alcohol Research Centre (NDARC), UNSW Australia, Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Doab","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre, Kings Cross, P.O. Box 22, Sydney, NSW 1340, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-9677","authenticated-orcid":false,"given":"Vincent J.","family":"Cornelisse","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre, Kings Cross, P.O. Box 22, Sydney, NSW 1340, Australia"},{"name":"Kirby Institute, UNSW Australia, Sydney, NSW 2032, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Gilliver","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre, Kings Cross, P.O. Box 22, Sydney, NSW 1340, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021). Interim Guidance for Country Validation of Viral Hepatitis Elimination, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kwon, J.A., Dore, G.J., Hajarizadeh, B., Alavi, M., Valerio, H., Grebely, J., Guy, R., and Gray, R.T. (2021). Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257369"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103422","DOI":"10.1016\/j.drugpo.2021.103422","article-title":"Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort","volume":"96","author":"Carson","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S-1324","DOI":"10.1016\/S0016-5085(20)33982-2","article-title":"High Svr Rates in 1612 Patients with Multiple Comorbid Medical Conditions, Including Esrd, Treated with Hcv Daas in Community Practice Using a Specialized Pharmacy Team","volume":"158","author":"Kim","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S0168-8278(18)30843-2","article-title":"Universal access to DAA therapy paves theway for HCV control and elimination among people living with HIV in Australia","volume":"68","author":"Martinello","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_6","first-page":"41","article-title":"CROI 2019: Highlights of viral hepatitis","volume":"27","author":"Luetkemeyer","year":"2019","journal-title":"Top. Antivir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.jve.2020.06.001","article-title":"Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries","volume":"6","author":"Barber","year":"2020","journal-title":"J. Virus Erad."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13027-016-0071-z","article-title":"Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States","volume":"11","author":"Rosenthal","year":"2016","journal-title":"Infect Agent Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103418","DOI":"10.1016\/j.drugpo.2021.103418","article-title":"Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada","volume":"96","author":"Selfridge","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: A population-based cohort study","volume":"2","author":"Islam","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100580","DOI":"10.1016\/j.jhepr.2022.100580","article-title":"HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates","volume":"4","author":"Lens","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S0618-8278(19)31463-X","article-title":"HCV re-infection among HIV-infected MSM in New York City","volume":"70","author":"Carollo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","unstructured":"Gastroenterological Society of Australia (2020). Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement (June 2020), Gastroenterological Society of Australia."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00508-021-01868-1","article-title":"Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use","volume":"133","author":"Bota","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Douglass, C.H., Pedrana, A., Lazarus, J.V., \u2018t Hoen, E.F.M., Hammad, R., Leite, R.B., Hill, A., and Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med., 16.","DOI":"10.1186\/s12916-018-1162-z"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/apt.15210","article-title":"Treatment access is only the first step to hepatitis C elimination: Experience of universal anti-viral treatment access in Australia","volume":"49","author":"Doyle","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_18","unstructured":"(2024, March 15). Kirby Institute Monitoring Hepatitis C Treatment Uptake in Australia (Issue 10). Available online: https:\/\/kirby.unsw.edu.au\/report\/monitoring-hepatitis-c-treatment-uptake-australia-issue-10-june-2019."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/jvh.13013","article-title":"Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study","volume":"26","author":"Kwon","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S-1324","DOI":"10.1016\/S0016-5085(20)33981-0","article-title":"Treating Hepatitis C in Marginalized Populations: A Low-Barrier Approach from an Internal Medicine Resident Primary Care Clinic","volume":"158","author":"Austin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109050","DOI":"10.1016\/j.drugalcdep.2021.109050","article-title":"Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system","volume":"228","author":"Gibbs","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","article-title":"Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis","volume":"73","author":"Grebely","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","unstructured":"StataCorp (2023). Stata Statistical Software: Release 18, StataCorp LLC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/dar.13723","article-title":"Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study","volume":"42","author":"Hobday","year":"2023","journal-title":"Drug Alcohol Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/jvh.13803","article-title":"Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)","volume":"30","author":"Carson","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_27","unstructured":"Heard, S., Zolala, F., and Maher, L. (2023). Australian Needle Syringe Program Survey National Data Report 2018\u20132022: Prevalence of HIV, HCV and Injecting and Sexual Behaviour among NSP Attendees, Kirby Institute, UNSW Sydney."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Australian Institute of Health and Welfare (2018). Australia\u2019s Health 2018: In Brief.","DOI":"10.21820\/23987073.2018.2.80"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14443058.2020.1796754","article-title":"White Medicine, White Ethics: On the Historical Formation of Racism in Australian Healthcare","volume":"44","author":"Mayes","year":"2020","journal-title":"J. Aust. Stud."},{"key":"ref_30","first-page":"54","article-title":"Decolonising the mind: Working with transgenerational trauma and first nations people","volume":"31","year":"2019","journal-title":"Judic. Off. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13012-019-0920-4","article-title":"Implementation effectiveness of health interventions for indigenous communities: A systematic review","volume":"14","author":"Harding","year":"2019","journal-title":"Implement. Sci."},{"key":"ref_32","unstructured":"University of New South Wales (2022, September 01). Deadly Liver Mob. Available online: https:\/\/www.deadlylivermob.org\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/add.16113","article-title":"Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies","volume":"118","author":"Iversen","year":"2023","journal-title":"Addiction"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis c reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","first-page":"49","article-title":"Reinfection following successful direct acting antiviral therapy for hepatitis C infection among people who inject drugs","volume":"3","author":"Cunningham","year":"2020","journal-title":"Can. Liver J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jvh.12701","article-title":"Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005\u20132014: The HITS- p study","volume":"24","author":"Cunningham","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis C virus following sustained virological response in injection drug users","volume":"25","author":"Grebely","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/cid\/ciad127","article-title":"Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston","volume":"77","author":"Beiser","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2022.09.011","article-title":"National trends in retreatment of HCV due to reinfection or treatment failure in Australia","volume":"78","author":"Carson","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/QAD.0000000000002562","article-title":"Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV","volume":"34","author":"Martinello","year":"2020","journal-title":"AIDS"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciz985","article-title":"Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study","volume":"71","author":"Martinello","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12939-019-0941-2","article-title":"Health care equity and access for marginalised young people: A longitudinal qualitative study exploring health system navigation in Australia","volume":"18","author":"Robards","year":"2019","journal-title":"Int. J. Equity Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/cit297","article-title":"Peer Support Models for People With a History of Injecting Drug Use Undertaking Assessment and Treatment for Hepatitis C Virus Infection","volume":"57","author":"Crawford","year":"2013","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:58:04Z","timestamp":1760108284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060957"],"URL":"https:\/\/doi.org\/10.3390\/v16060957","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}